8-K: Shattuck Labs Reports Q1 2025 Financial Results and Advances SL-325 Program

Shattuck Labs announces its Q1 2025 financial results, highlighting progress with its SL-325 program and a cash balance expected to fund operations into 2027.

Summary

• Shattuck Labs reported its financial results for the first quarter ended March 31, 2025.
• The company is advancing its SL-325 program, with an IND filing expected in the third quarter of 2025.
• Shattuck's cash balance as of March 31, 2025, was approximately $60.9 million, which is expected to fund operations into 2027.
• R&D expenses for the quarter were $9.9 million, compared to $16.3 million in the same quarter of the previous year.
• General and administrative expenses were $4.5 million, compared to $4.9 million in the first quarter of 2024.
• The net loss for the quarter was $13.7 million, or $0.27 per share, compared to a net loss of $18.5 million, or $0.37 per share, for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress with SL-325, the favorable safety data, and the extended cash runway. However, the company is still operating at a loss, which tempers the overall sentiment.

Positives

• Shattuck Labs has a strong cash position of $60.9 million, expected to fund operations into 2027.
• The company is making progress with its SL-325 program, with an IND filing expected in Q3 2025.
• Preclinical studies of SL-325 have shown a favorable safety profile.
• The company has completed wind-down activities associated with the discontinued oncology programs.
• The net loss has decreased compared to the same quarter last year.

Negatives

• The company is still operating at a loss, with a net loss of $13.7 million for the quarter.
• Cash reserves have decreased from $114.6 million as of March 31, 2024, to $60.9 million as of March 31, 2025.

Risks

• The company's future success depends on the successful development and commercialization of its product candidates, particularly SL-325.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company may need to raise additional capital in the future to fund its operations.
• Global macroeconomic conditions and related volatility could impact the company's operations and financial results.

Future Outlook

Shattuck Labs expects its current cash and cash equivalents to fund operations into 2027, based on current operational plans and excluding any additional capital that may be received or proceeds from business development transactions.

Management Comments

• We believe SL-325 is fundamentally differentiated in its approach to targeting the clinically validated DR3/TL1A pathway and could potentially provide best-in-class clinical remission rates for IBD patients, said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
• Spending last quarter continued to come in line with expectations, and wind-down activities associated with the discontinued oncology programs have now been substantially completed.
• We continue to be well-positioned to fund operations into 2027, beyond the results from our Phase 1 clinical trial for SL-325.

Industry Context

Shattuck Labs is focused on developing novel therapeutics targeting TNF superfamily receptors, a competitive area with other companies also pursuing treatments for inflammatory and immune-mediated diseases. The DR3/TL1A pathway is a validated target, and Shattuck's SL-325 aims to offer a differentiated approach compared to existing TL1A blocking antibodies.

Comparison to Industry Standards

• Shattuck is developing SL-325, a DR3 antagonist antibody, for IBD, which is a different approach than companies like Prometheus Biosciences (acquired by Merck) and Roivant Sciences who are developing TL1A inhibitors.
• The preclinical safety data for SL-325 in NHPs, with a No Observed Adverse Effect Level of 100mg/kg, is a positive indicator, but will need to be confirmed in human clinical trials.
• The projected cash runway into 2027 provides Shattuck with a longer period to achieve clinical milestones compared to some smaller biotech companies.

Stakeholder Impact

• Shareholders: The progress with SL-325 and the extended cash runway are positive for shareholders.
• Employees: The continued funding of operations provides job security for employees.
• Patients: The development of SL-325 could potentially provide a new treatment option for patients with IBD and other inflammatory and immune-mediated diseases.

Next Steps

• File an IND for SL-325 in the third quarter of 2025.
• Initiate a Phase 1 clinical trial for SL-325 in the third quarter of 2025.
• Nominate a lead bispecific candidate from its preclinical pipeline in 2025.
• Present at the PEGS Boston Summit on May 12, 2025.
• Participate in the Leerink Partners Therapeutics Forum on July 8-9, 2025.

Key Dates

Keywords

SL-325, DR3 antagonist, IBD, inflammatory bowel disease, Shattuck Labs, financial results, biotechnology, TNF superfamily receptors, clinical trial, IND filing